37 results on '"Mejías-Pérez, Ernesto"'
Search Results
2. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern
3. Rapid, efficient and activation-neutral gene editing of polyclonal primary human resting CD4+ T cells allows complex functional analyses
4. Neutrophil subtypes shape HIV-specific CD8 T-cell responses after vaccinia virus infection
5. Spatial resolution of HIV-1 post-entry steps in resting CD4 T cells
6. Rapid, efficient and activation-neutral gene editing of polyclonal primary human resting CD4+ T cells allows complex functional analyses
7. NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses
8. Unterdrückung der SARS‐CoV‐2‐Replikation mit stabilisierten und durch Klick‐Chemie modifizierten siRNAs
9. Suppression of SARS‐CoV‐2 Replication with Stabilized and Click‐Chemistry Modified siRNAs
10. Superior immunity that allows neutralization of all SARS-CoV-2 variants of concern develops in COVID-19 convalescents and naïve individuals after three vaccinations
11. The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1
12. The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1
13. Vectores virales basados en poxvirus como agentes oncolíticos
14. Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways
15. Rapid, efficient and activation-neutral gene editing of polyclonal primary human resting CD4+T cells allows complex functional analyses
16. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells
17. Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response
18. A Prime/Boost PfCS14K M /MVA-sPfCS M Vaccination Protocol Generates Robust CD8 + T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria
19. The evolution of poxvirus vaccines
20. Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression
21. The Evolution of Poxvirus Vaccines
22. Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles
23. Optimizacion de una vacuna frente a la leishmaniasis
24. Bivalent NYVAC-based Vaccine Candidates against HIV/AIDS Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs
25. Vaccinia Virus with Selective Deletions Enhances T Cell Response to HIV Antigens by Specific Neutrophil Recruitment
26. New vaccinia virus promoter as a potential candidate for future vaccines
27. Attenuated and Replication-Competent Vaccinia Virus Strains M65 and M101 with Distinct Biology and Immunogenicity as Potential Vaccine Candidates against Pathogens
28. High Quality Long-Term CD4+ and CD8+ Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in Leishmania major BALB/c Model of Infection
29. High Quality Long-Term CD4+ and CD8+ Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in Leishmania major BALB/c Model of Infection.
30. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells.
31. A Prime/Boost PfCS14KM/MVA-sPfCSMVaccination Protocol Generates Robust CD8+T Cell and Antibody Responses to Plasmodium falciparumCircumsporozoite Protein and Protects Mice against Malaria
32. Bivalent NYVAC-based Vaccine Candidates against HIV/AIDS Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs.
33. Vaccinia Virus with Selective Deletions Enhances T Cell Response to HIV Antigens by Specific Neutrophil Recruitment.
34. Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles.
35. Suppression of SARS-CoV-2 Replication with Stabilized and Click-Chemistry Modified siRNAs.
36. Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways.
37. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8 + T cells.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.